Date: 2013-04-16
Type of information: Distribution agreement
Compound: DNA tests for tamoxifen, statins and clopidogrel
Company: Stada (Germany) Humatrix (Germany)
Therapeutic area: Diagnostic - Cancer - Oncology - Cardiovascular diseases
Type agreement: distribution
Action mechanism:
Disease:
Details: Stada is entering the personalized drug therapy business. The company has concluded an exclusive distribution agreement with the Frankfurt biotechnology company humatrix. Under the name \"Stada Diagnostik\" Stada will subsequently market a range of DNA tests that offer patients greater treatment safety with regard to the correct choice of medication for their illness. Tests on individual tolerability and effectiveness of three pharmaceutical products and categories of active ingredients – Tamoxifen for the treatment of breast cancer, statins for reducing an elevated cholesterol level and Clopidogrel for protection in case of an increased risk of heart attack and thrombosis – will be available throughout Germany at selected pharmacies in the coming weeks. In the medium term, patients will be provided with easy access to the tests nationwide.
Financial terms:
Latest news:
